Filing Flows › Myriad Genetics (MYGN) › Q2 2026 › vs Q2 2025
Myriad Genetics (MYGN) Q2 2026 vs Q2 2025 (year over year)
Myriad Genetics's revenue fell $22.4M (-11%) from $213M in Q2 2025 to $191M in Q2 2026. The biggest changes: Cancer Care Continuum −$13.6M (-11%); Prenatal Health −$7.8M (-16%); Mental Health −$1.0M (-3%).
Myriad Genetics, Q2 2026: revenue $191M (-10% year over year), operating margin -20.4%, net loss $43.2M, operating cash flow −$8.3M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Cancer Care Continuum | $114M | $128M | −$13.6M | -11% |
| Prenatal Health | $39.8M | $47.6M | −$7.8M | -16% |
| Mental Health | $36.8M | $37.8M | −$1.0M | -3% |
| Revenue | $191M | $213M | −$22.4M | -11% |
| Net loss | $43.2M | $330M | −$287M | -87% |
| Costs & expenses | $234M | $544M | −$310M | -57% |
| Operating costs | $230M | $542M | −$313M | -58% |
| Interest & other, net | $3.7M | $1.4M | $2.3M | +164% |
| Income tax | $600K | −$100K | $700K | — |
| Cost of revenue | $63.7M | $61.3M | $2.4M | +4% |
| Research & development | $25.0M | $25.6M | −$600K | -2% |
| Sales & marketing | $83.1M | $71.9M | $11.2M | +16% |
| General & admin | $57.8M | $66.8M | −$9.0M | -13% |
| Operating cash sources | $43.2M | $330M | −$287M | -87% |
| Depreciation & amortization | $12.5M | $14.1M | −$1.6M | -11% |
| Share-based compensation | $7.2M | $10.7M | −$3.5M | -33% |
| Working capital & other | $15.2M | $292M | −$277M | -95% |
| Cash used in operations | $8.3M | $13.6M | −$5.3M | -39% |
| Net loss absorbed | $43.2M | $330M | −$287M | -87% |
Questions
How much did Myriad Genetics's revenue grow year over year in Q2 2026?
Myriad Genetics's revenue fell $22.4M (-11%) from $213M in Q2 2025 to $191M in Q2 2026.
What drove Myriad Genetics's revenue change in Q2 2026?
Cancer Care Continuum −$13.6M (-11%); Prenatal Health −$7.8M (-16%); Mental Health −$1.0M (-3%).